Donna Headlee

3.2k total citations
34 papers, 2.7k citations indexed

About

Donna Headlee is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Donna Headlee has authored 34 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Donna Headlee's work include Prostate Cancer Treatment and Research (8 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Donna Headlee is often cited by papers focused on Prostate Cancer Treatment and Research (8 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Donna Headlee collaborates with scholars based in United States, Malaysia and Japan. Donna Headlee's co-authors include William D. Figg, Edward A. Sausville, Adrian M. Senderowicz, A Tompkins, Susan G. Arbuck, Seth M. Steinberg, Michael R. Cooper, William D. Figg, Alain Thibault and Richard M. Lush and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Internal Medicine.

In The Last Decade

Donna Headlee

34 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Donna Headlee United States	24	1.5k	1.1k	559	330	328	34	2.7k
J Mattern Germany	30	1.7k 1.2×	1.5k 1.4×	520 0.9×	269 0.8×	731 2.2×	140	3.4k
Richard Kendall United States	24	1.8k 1.2×	837 0.8×	268 0.5×	324 1.0×	476 1.5×	43	3.0k
Volker Wacheck Austria	35	2.3k 1.6×	1.0k 0.9×	480 0.9×	496 1.5×	474 1.4×	113	3.6k
Kenneth Kolinsky United States	19	1.3k 0.9×	1.3k 1.2×	350 0.6×	326 1.0×	294 0.9×	33	2.3k
Young Hwa Soung South Korea	30	2.3k 1.6×	1.2k 1.1×	621 1.1×	262 0.8×	669 2.0×	70	3.2k
Kathryn Packman United States	28	2.6k 1.7×	2.2k 2.1×	481 0.9×	286 0.9×	484 1.5×	65	3.9k
Bill Spohn United States	13	2.4k 1.6×	1.3k 1.2×	416 0.7×	273 0.8×	485 1.5×	20	3.2k
Masahiko Nishiyama Japan	33	1.6k 1.1×	1.3k 1.2×	842 1.5×	240 0.7×	680 2.1×	188	3.3k
Mahmoud Toulany Germany	32	1.9k 1.3×	1.1k 1.0×	716 1.3×	238 0.7×	603 1.8×	59	3.0k
Sean K. Kelley United States	15	1.3k 0.9×	773 0.7×	503 0.9×	348 1.1×	348 1.1×	19	2.1k

Countries citing papers authored by Donna Headlee

Since Specialization

Citations

This map shows the geographic impact of Donna Headlee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donna Headlee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donna Headlee more than expected).

Fields of papers citing papers by Donna Headlee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donna Headlee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donna Headlee. The network helps show where Donna Headlee may publish in the future.

Co-authorship network of co-authors of Donna Headlee

This figure shows the co-authorship network connecting the top 25 collaborators of Donna Headlee. A scholar is included among the top collaborators of Donna Headlee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donna Headlee. Donna Headlee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Figg, William D., Manish Monga, Donna Headlee, et al.. (2014). A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms. Cancer Chemotherapy and Pharmacology. 74(5). 955–967. 15 indexed citations

Headlee, Donna, Yusri Elsayed, Alex Sparreboom, et al.. (2004). A first in human trial of an oral histone deacetylase inhibitor, MS-275, in advanced solid tumor and lymphoma patients.. Cancer Research. 64. 567–567. 2 indexed citations

Zhai, Suoping, Edward A. Sausville, Adrian M. Senderowicz, et al.. (2003). Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anti-Cancer Drugs. 14(2). 125–135. 20 indexed citations

Rudek, Michelle A., Kenneth S. Bauer, Richard M. Lush, et al.. (2003). Clinical Pharmacology of Flavopiridol following a 72-Hour Continuous Infusion. Annals of Pharmacotherapy. 37(10). 1369–1374. 36 indexed citations

Sausville, Edward A., Susan G. Arbuck, Richard A. Messmann, et al.. (2001). Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms. Journal of Clinical Oncology. 19(8). 2319–2333. 234 indexed citations

Bergan, Raymond C., E Reed, Catherine E. Myers, et al.. (1999). A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.. PubMed. 5(9). 2366–73. 78 indexed citations

Sausville, Edward A., Daniel Zaharevitz, Laurent Meijer, et al.. (1999). Cyclin-Dependent KinasesInitial Approaches to Exploit a Novel Therapeutic Target. Pharmacology & Therapeutics. 82(2-3). 285–292. 95 indexed citations

Senderowicz, Adrian M., Donna Headlee, Sherman F. Stinson, et al.. (1998). Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.. Journal of Clinical Oncology. 16(9). 2986–2999. 338 indexed citations

Dawson, Nancy A., William D. Figg, Otis W. Brawley, et al.. (1998). Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.. PubMed. 4(1). 37–44. 20 indexed citations

10.

Bergan, Raymond C., William D. Figg, Nancy A. Dawson, et al.. (1997). Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.. PubMed. 89(9). 622–8. 11 indexed citations

11.

Dawson, Nancy A., Richard M. Lush, Seth M. Steinberg, et al.. (1996). Suramin-induced neutropenia. European Journal of Cancer. 32(9). 1534–1539. 9 indexed citations

12.

Figg, William D., Nancy A. Dawson, Oliver Sartor, et al.. (1996). A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer : toxicity and response. Cancer Chemotherapy and Pharmacology. 39(1-2). 1–8. 34 indexed citations

13.

Lush, Richard M., William D. Figg, James M. Pluda, et al.. (1996). A phase I study of pentosan polysulfate sodium in patients with advanced malignancies. Annals of Oncology. 7(9). 939–944. 23 indexed citations

14.

Dawson, Nancy A., Michael R. Cooper, William D. Figg, et al.. (1995). Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer. 76(3). 453–462. 63 indexed citations

15.

Piscitelli, Stephen C., Alain Thibault, William D. Figg, et al.. (1995). Disposition of Phenylbutyrate and its Metabolites, Phenylacetate and Phenylacetylglutamine. The Journal of Clinical Pharmacology. 35(4). 368–373. 53 indexed citations

16.

Thibault, Alain, Dvorit Samid, Michael R. Cooper, et al.. (1995). Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer. 75(12). 2932–2938. 110 indexed citations

17.

Figg, William D., Alain Thibault, Michael R. Cooper, et al.. (1995). A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer. 75(8). 2159–2164. 40 indexed citations

18.

Bitton, Roberto, William D. Figg, David Venzon, et al.. (1995). Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.. Journal of Clinical Oncology. 13(9). 2223–2229. 29 indexed citations

19.

Sartor, Oliver, Michael R. Cooper, Donna Headlee, et al.. (1994). Surprising Activity of Flutamide Withdrawal, When Combined With Aminoglutethimide, in Treatment of "Hormone-Refractory" Prostate Cancer. JNCI Journal of the National Cancer Institute. 86(3). 222–227. 112 indexed citations

20.

Thibault, Alain, Michael R. Cooper, William D. Figg, et al.. (1994). A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer.. PubMed. 54(7). 1690–4. 141 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact